Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

This study is testing a combination of two drugs — tafasitamab (an antibody targeting cancer cells) and lenalidomide (an immune-modulating drug) — for people with lymphoma that has come back in the brain or spinal fluid (called CNS lymphoma). This is a difficult-to-treat condition with limited options. **You may be eligible if...** - You are 18 or older with relapsed DLBCL-type CNS lymphoma (brain, spinal fluid, or eye involvement) - You have received at least one prior treatment - Your organ function meets requirements and your performance status is adequate (ECOG 0–1) - You have an anticipated survival of more than 2 months **You may NOT be eligible if...** - You have received anti-CD19 therapy or CAR-T cell therapy previously - You have HIV - You have had systemic cancer therapy within the past 2 weeks, or antibody therapy within the past 4 weeks - You are known to be allergic to lenalidomide or tafasitamab - You are pregnant or breastfeeding, or unwilling to use effective contraception - You have CNS post-transplant lymphoproliferative disease Talk to your doctor to see if this trial is right for you.